Human Papillomavirus Education Programs
2 other identifiers
interventional
12
1 country
1
Brief Summary
This clinical trial aims to implement a culturally-tailored educational outreach actives with the goal of increasing knowledge of human papillomavirus (HPV) types that can lead to cancer and uptake of the available vaccine. The initiative also addresses barriers to vaccination and refer people to sites where they can get the HPV vaccine (e.g., private doctor offices, community health clinics, school-based health centers, and health departments). The HPV education program may help increase HPV vaccination rates and ultimately prevent HPV-related cancers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 6, 2021
CompletedFirst Posted
Study publicly available on registry
May 11, 2021
CompletedStudy Start
First participant enrolled
April 27, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedNovember 2, 2023
October 1, 2023
8 months
May 6, 2021
October 31, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Change in human papillomavirus (HPV) knowledge
Change in knowledge and strength of intention to be vaccinated will be correlated with key outcomes, specifically actual vaccination and actions promoting vaccination (e.g., encouraging HPV vaccination with family/friends, talking to their doctor/provider about the HPV vaccine). Multivariable logistic regression analyses will be conducted to examine the impact of knowledge change and strength of intentions on these binary outcomes (vaccinated/not vaccinated and encouraged/did not encourage HPV vaccination) controlling for important covariates such as age, sex, race/ethnicity, education, primary language, and health insurance/health care coverage.
Baseline up to 6 months
Study Arms (1)
Prevention (educational session, handout, survey)
EXPERIMENTALParticipants attend educational session about HPV-related cancers, screening, and HPV vaccination and guidelines and receive informational infographic handout on HPV vaccination. Participants also complete surveys pre and post education session over 5 minutes each to assess HPV vaccination status among children of participants, HPV knowledge, and intentions to get the HPV vaccination, and screening among participants. In addition, participants complete surveys over telephone or face-to-face at 3 and 6 months.
Interventions
Attend educational session
Eligibility Criteria
You may qualify if:
- years of age and older
- From Ohio
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Electra D Paskett, PhD
Ohio State University Comprehensive Cancer Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 6, 2021
First Posted
May 11, 2021
Study Start
April 27, 2022
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
November 2, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will not share